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REVIEW
Abstract: Insulin detemir is a soluble long-acting human insulin analogue at neutral pH
with a unique mechanism of action. Following subcutaneous injection, insulin detemir binds
to albumin via fatty acid chain, thereby providing slow absorption and a prolonged metabolic
effect. Insulin detemir has a less variable pharmacokinetic profile than insulin suspension
isophane or insulin ultralente. The use of insulin detemir can reduce the risk of hypoglycemia
(especially nocturnal hypoglycemia) in type 1 and type 2 diabetic patients. However, overall
glycemic control, as assessed by glycated hemoglobin, is only marginally and not significantly
improved compared with usual insulin therapy. The weight gain commonly associated with
insulin therapy is rather limited when insulin detemir is used. In our experience, this new
insulin analogue is preferably administrated at bedtime but can be proposed twice a day (in
the morning and either before the dinner or at bedtime). Detemir is a promising option for
basal insulin therapy in type 1 or type 2 diabetic patients.
Keywords: diabetes mellitus, insulin detemir, hypoglycemia, insulin analogue, insulin therapy
Introduction
The history of treatment for diabetic patients can be resumed in several milestones.
More than eighty years ago, insulin was discovered and it is probably one of the
greatest medical advances of the 20th century (Rosenfeld 2002). Manufacturing
techniques improved rapidly but the origin of the insulin proposed to diabetic patients
was still inadequate (bovine and porcine sources). The first long-acting preparation,
protamine zinc insulin, was developed in order to reduce the number of injections
necessary for adequate insulin replacement (Joslin 1941). This preparation was often
used once daily, without the addition
 of regular insulin. Later, insulin neutral protamine
Hagedorn (NPH) and insulin zinc
 (Lente) were introduced. Then, a movement toward
more complete coverage of insulin requirements resulted in the twice daily mix
regimen of NPH and regular insulin (Jackson 1986). Nevertheless, the best definition
for physiological insulin replacement consists of prandial (bolus) insulin, basal
insulin, and a correction-dose insulin supplement when necessary (DeWitt and
Hirsch 2003).
Another big step in insulin therapy was effective when the development of purified
pork insulin
 and then recombinant human insulin virtually eliminated insulin
 allergy
and immune-mediated lipoatrophy (McNally et al 1988).
Despite many improvements in the management of diabetes, the
nonphysiological time-action profiles of conventional insulin formulations remain
a significant obstacle. In 1993 and 1998, the reports of the Diabetes Control and
Complications
 Trial (DCCT 1993) and the United Kingdom Prospective Diabetes
Study (UKPDS 1998), respectively, confirmed
 the value of glycemic control in
the delay or prevention of
 complications of diabetes. The limiting pharmacokinetic
and
 pharmacodynamic features of standard insulins, which frequently lead to
hypoglycemia as glycosylated hemoglobin (HbA1C) values approach
 the normal
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range, renewed interest in producing safer insulin
formulations that more closely mimic the basal and
mealtime
 components of endogenous insulin secretion.
This interest has
 yielded insulin analogues that are
characterized by action profiles
 that afford more flexible
treatment regimens with a lower risk
 of hypoglycemia
(Hirsch 2005).
The first insulin analogues used in insulin therapy
were the rapid-acting insulin analogues (aspart and
lispro): their pharmacodymamic properties are
particularly interesting because their profile is closer to
the physiologic profile of postprandial endogenous
insulin (Mudaliar et al 1999). They are able to decrease
glycemia more rapidly than usual rapid-acting insulin
preparations (regular); the peak insulin action occurs
approximately twice as fast with analogues as with
regular insulin. The more rapid pharmacodynamic effects
of insulin lispro and insulin aspart make postabsorptive
hypoglycemia less of a problem with these analogues than
with regular insulin (Hirsch 2005).
The first long-acting insulin analogue, insulin
glargine,
 was introduced in the US in spring 2001. This
analogue is produced by the substitution of the asparagine
by a glycine at position A21 of the insulin molecule and
by the addition of two arginine molecules at position B30
(Heinemann et al 2000). These
 changes lead to a shift in
the isoelectric point toward a neutral
 pH, which results
in an insulin molecule that is less soluble
 at the injection
site and that precipitates in the subcutaneous
 tissue to
form a deposit from which insulin is slowly released (Yki-
Jarvinen et al 2000).
Later on, insulin detemir was introduced and is now
available as the last insulin analogue proposed for insulin
therapy. The advantages and properties of this new basal
human insulin analogue are discussed in this article.
Pharmacodynamic and
pharmacokinetic properties
Insulin detemir is a neutral, soluble, long-acting insulin
analogue in which threonine is omitted from position B30
of the insulin β-chain and replaced by myristic acid, a C14
fatty acid chain (Figure 1). This fatty acid modification
allows insulin detemir to reversibly bind to the long-chain
fatty acid binding sites (Havelund
 et al 2004). Insulin detemir
is soluble at neutral pH, which enables it to remain in a
liquid form following subcutaneous injection, unlike NPH
insulin and glargine. The solubility of insulin detemir may
be a factor contributing to the reduced variability in glycemic
control observed in recipients of this agent compared with
NPH or glargine because precipitation and dissociation of
a precipitate are unpredictable processes. Anyway,
comparison of intra-subject variability of glucose-lowering
action between detemir and glargine use is still limited since
the paper documenting this possible better stability of
glucose levels with detemir is based on a comparison after
four injections of each insulin analogue in a limited number
of patients (Heise et al 2004). So far, there is no extended
clinical study on such a comparison available. A trial
designed to describe the 24 h pharmacodynamic profile
(including duration of action and dose-response relationship)
of insulin detemir in subjects with type 1 diabetes reported
that insulin detemir provides a flat and protracted
pharmacodynamic profile. This study used a 24 h
isoglycemic clamp and showed a linear dose response over
a range of clinically relevant doses (Plank et al 2005). These
data were also confirmed in a crossover trial including
children, adolescents and adults who received
subcutaneous single doses of 0.5 units/kg insulin detemir
or 0.5 IU/kg NPH insulin on two separate days. Less total
variability in the pharmacokinetics of insulin detemir than
Figure 1 Structure of insulin detemir.Vascular Health and Risk Management 2006:2(3) 279
Insulin detemir for treating diabetes
NPH insulin was observed in all three age-groups (Danne
et al 2003).
Following subcutaneous injection, insulin detemir
binds to albumin and, at steady state, the concentration
of free, unbound insulin is then greatly reduced, resulting
in more stable plasma insulin levels. The protracted action
of insulin detemir, achieved by slow absorption from the
subcutaneous depot, appears to be mediated via two
mechanisms: initially, self association of the insulin
detemir molecule at the site of injection and,
subsequently, binding to albumin via fatty acid chain
(Havelund
 et al 2004). Although few data are available
in humans, there is no major relationship between
pharmacodynamic and pharmacokinetic properties of
detemir and the plasma level of albumin (perhaps except
in severe hypoalbuminemia). A significant relationship
between the injected dose of insulin detemir and its
duration of hypoglycemic action has been recently
reported (Plank et al 2005), and such observation may
influence the use of insulin detemir in one or two
injections per day to insure basal insulin levels over the
24 h period (Oiknine et al 2005).
Insulin detemir acts as a full agonist of the insulin
receptor but dissociates from the insulin receptor twice
as fast as human insulin in vitro. This finding explains
the fact that insulin detemir demonstrated lower metabolic
potency than human insulin. The drug has been shown to
have molar potency approximately 25% lower than that
of human insulin in patients with diabetes (Kurtzhals
2004). For this reason, insulin detemir is formulated at a
molar concentration four times higher than that of human
insulin.
Some data suggest that insulin detemir, when compared
with NPH insulin, has a greater effect on the liver than on
peripheral tissues (Hordern et al 2005). As discussed below,
this particularity may explain some particular clinical
observations.
When creating new insulin analogues, the risk of
mitogenicity is an important and potentially dangerous
adverse event to look after. The affinity of insulin detemir
for the insulin-like growth factor-1 receptor is about 16%
(100% for human insulin) and the mitogenic potency of the
drug is low (Kurtzhals et al 2000).
Concerning metabolism and elimination, human insulin
is internalized after binding to its receptor and the same is
presumed for insulin detemir. Data suggest an elimination
half-life of 6.8 minutes which is five to six times more slowly
than human insulin.
Clinical efficacy in type 1 diabetes
The clinical efficacy, tolerability, and safety of insulin
detemir has been studied in several large (number of subjects
>250), randomized, parallel-group, multicenter trials of 16–
26 weeks duration in adults with type 1 diabetes (Hermansen
et al 2001, Hermansen, Fontaine, et al 2004; Home et al
2004). Some publications also reported results with 12-
month data from two extension studies (Standl et al 2004;
De Leeuw et al 2005). A recent large trial in children and
adolescents with type 1 diabetes is also available (Robertson
et al 2004). In all these trials, insulin detemir was compared
with NPH insulin (Table 1).
Glucose control, as assessed by HbA1C fasting plasma
glucose (FPG) levels, or 9-point blood glucose profiles, was
similar to, or better than, that with NPH insulin (Vague et al
2003; Hermansen et al 2001; Home et al 2004; Standl et al
2004; Pieber et al 2005). Use of insulin detemir, administered
once or twice daily, in combination with bolus insulin aspart
or regular human insulin, resulted in FPG levels similar to
or lower than those achieved when treating patients with
NPH plus insulin aspart or regular.
Importantly, insulin detemir was generally associated
with more predictable glycemic control and less intra-patient
variability than NPH insulin (Vague et al 2003; Hermansen
et al 2001; Home et al 2004; Pieber et al 2005). Intra-patient
variation in self-measured plasma or blood glucose was
lower with insulin detemir than with NPH insulin in most
trials. Glucose fluctuations (defined as the area between the
individual glucose curve and its mean level) based on
continuous glucose monitoring over 24 h and during the
night were reported in a subgroup of patients after 5 months
treatment, these glucose fluctuations over 24 h or at night
were significantly lower with insulin detemir than with NPH
insulin (Russell-Jones et al 2004).
Clinical evidence from different trials has shown a
similar or lower risk of hypoglycemia (particularly nocturnal
hypoglycemia) with insulin detemir compared with NPH
insulin. Most of the trials report a significant (p<0.05)
reduction in the risk of nocturnal hypoglycemia in recipients
of insulin detemir compared with NPH insulin (Hermansen
et al 2001; Chapman and Perry 2005). For example, a trial
aimed to compare insulin analogues (insulin detemir, insulin
aspart) versus traditional human insulins (insulin NPH,
insulin regular) in type 1 diabetic patients with basal-
bolus therapy showed interesting results in term of
hypoglycemic events, numbers of overall hypoglycemia
episodes per person-year were 37.1 and 48.2 for the
insulin detemir and insulin NPH, respectively, whileVascular Health and Risk Management 2006:2(3) 280
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corresponding numbers of nocturnal hypoglycemia
episodes per person-year were 4.0 and 9.2, respectively
(Hermansen, Fontaine, et al 2004).
Weight gain with insulin detemir use is rather limited
when compared to insulin NPH. After 16–52 weeks of
treatment, patients with type 1 diabetes receiving insulin
detemir had a significantly (p<0.001) lower mean
bodyweight or a significantly (p=0.002) lower bodyweight
gain adjusted for change in HbA1C than NPH insulin
recipients (Vague et al 2003; Standl et al 2004). The
explanation for this interesting observation is still unclear
and discussed below.
Clinical efficacy in type 2 diabetes
Two trials had reported data about insulin detemir in
combination with mealtime insulin aspart (like the usual
insulin therapy in type 1 diabetes) (Haak et al 2003;
Raslova et al 2004). This association produced glycemic
control similar to that of NPH insulin plus either insulin
aspart or regular human insulin. In terms of HbA1C levels,
mean FPG levels, and self-measured blood glucose
profiles, there were no difference at the end of the
treatment in the two trials. Intra-individual variation in
FPG levels was, however, significantly lower in patients
receiving insulin detemir. The risk of hypoglycemia
(during the day and/or the night) was generally reduced
when using insulin detemir as compared with NPH insulin
although differences between the two groups were not
always statistically significant (Raslova et al 2003; Haak
et al 2004; Hermansen, Derezinski, et al 2004). While
the frequency of hypoglycemia (especially severe events)
is an important issue in some patients, it is less important
in type 2 diabetic compared with type 1 diabetic patients.
An important point, especially in the context of type
2 diabetes, is that insulin detemir was consistently
associated with significantly less bodyweight gain than
NPH. This effect may be considered as a relevant clinical
benefit concerning the optimal treatment of patients with
type 2 diabetes. Insulin therapy is often delayed because
of the risk of weight gain when stopping oral antidiabetic
drugs for insulin injections. A recent trial showed that,
in type 2 diabetic patients with impaired metabolic control
with oral agents, the use of insulin detemir versus insulin
NPH plus oral agents was associated with less
bodyweight gain and hypoglycemic events (Hermansen,
Derezinski, et al 2004). There is no clear explanation for
the lesser weight gain with insulin detemir as compared
with NPH insulin. This may be a consequence of the
increased predictability and smoother and more consistent
pharmacodynamic profile of insulin detemir, resulting in
reduced risk of hypoglycemia. Patients may be able to
reduce defensive eating against hypoglycemia while
maintaining more optimal blood glucose levels (Fritsche
and Haring 2004). However, the reduction of
hypoglycemic events does not seem to fully explain this
effect because no prevention of weight gain has been
reported with the use of glargine despite the fact that this
insulin also reduces the number of hypoglycemic episodes
in a similar extent to that reported with insulin detemir.
Because of its pharmacokinetic properties, insulin
detemir exerts greater effects on the liver than the
periphery. It has been suggested that systemic
hyperinsulinemia increases peripheral glucose uptake and
lipogenesis and decreases lipolysis, contributing to
weight gain associated with insulin therapy (Andreani
1999). Anyway, all these mechanisms that could explain
the favorable effects of insulin detemir on body weight
remain hypothetical.
Tolerability
All the data from randomized trials in type 1 and type 2
diabetes show that insulin detemir is well tolerated (Vague
et al 2003; Hermansen, Derezinski, et al 2004;
Hermansen, Fontaine, et al 2004; Home et al 2004;
Robertson et al 2004; Standl et al 2004; Chapman and
Perry 2005). Hypoglycemia was of course registered as
an endpoint in the different trials and it is reasonable to
consider these hypoglycemic episodes as a “usual”
iatrogenic effect. As already mentioned, the incidence of
hypoglycemic episodes was lower in diabetic patients
treated with insulin detemir as compared with NPH
insulin, especially at night. Otherwise, the nature and
incidence of adverse events observed with insulin detemir
are quite similar to those experienced with other human
insulin preparations (including insulin analogues)
(Chapman and Perry 2004). The majority of adverse
events was mild and considered unrelated to the study
drug (Chapman and Perry 2004).
Insulin detemir has not been studied in pregnant
diabetic women and should therefore not be proposed to
this special population.
Recently, the first case of type III allergy
 to the new
long-acting insulin analogue detemir was reported
(Darmon et al 2005). A severe injection site reaction to
insulin detemir has also been recently reported (Blumer
2006).Vascular Health and Risk Management 2006:2(3) 281
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Administration and posology
Insulin detemir can be used as basal therapy in conjunction
with short-acting bolus insulin in both patients with type 1
or type 2 diabetes (Chapman and Perry 2005). It can be
injected in the subcutaneous tissue one or two times a day.
Initially, it is recommended to inject insulin detemir in the
evening (at dinner or bedtime). Nevertheless, it was shown
that morning plus evening administration of insulin detemir
(plus insulin aspart at mealtime) provided also less variable
glucose levels with no, or less, weight gain than NPH insulin
administered in a similar way. Insulin detemir can be
administered either at dinner or bedtime, with similar
glycemic control (Pieber et al 2005). Adding short-acting
insulin analogue or rapid-acting insulin at mealtimes to
mimic as best as possible the normal insulin secretion is the
basis of the basal-bolus therapy. Such insulin regimen
particularly applies to insulin detemir administration. The
dose of insulin detemir has to be appreciated and adjusted
until the desired fasting plasma level has been attained. For
patients in whom the desired pre-dinner target blood glucose
level cannot be reached, it seems reasonable to split the total
daily dose of insulin detemir. Two separate injections
(morning and evening) may therefore be administrated.
Mixing insulin detemir with a rapid-acting insulin should
be avoided because the action profile of insulin detemir can
be modified with a lower and delayed maximum effect
compared with that provided by separate injections.
It appears that it is not necessary to make special
adjustments to the dosage of insulin detemir in children or
adolescents. It also seems safe to propose insulin detemir to
patients with renal or hepatic impairment. Indeed, despite
the fact that insulin detemir binds to albumin, no particular
adaptation in insulin detemir doses, as compared with NPH
insulin, is necessary for this kind of patient. Comparisons
between continuous subcutaneous insulin infusion and
multiple daily injections using insulin detemir (or insulin
glargine) have been limited until now and no relevant long-
term data are available yet.
Conclusions
Insulin detemir has been developed to ameliorate the profile
of usual human basal insulin. The advantage to avoid an
insulin peak and to keep a significant action for several hours
gives to insulin detemir appreciated properties for diabetic
patients. Despite the fact that rather few data are available
so far, insulin detemir may be responsible for less intra-
patient variability in glycemic control among patients with
type 1 diabetes compared with NPH insulin or insulin
glargine. Compared with NPH, use of insulin detemir may
be associated with a lower risk of hypoglycemia, especially
nocturnal hypoglycemia, in patients with type 1 or type 2
diabetes. This new insulin also provides the added clinical
benefit of no appreciable bodyweight gain in patients with
type 1 diabetes and less weight gain than NPH insulin in
patients with type 2 diabetes. The need to administer insulin
detemir twice a day to obtain a better basal insulin profile
compared with the unique injection of insulin glargine may
be a brake for detemir use in some patients.
In terms of overall glycemic control, there is no proof
of significant improvement in HbA1C levels when using
insulin detemir as compared with NPH insulin. Anyway,
the new properties of insulin analogues (basal and rapid
analogs) often give to diabetic patients some advantages
(more flexibility and lower rates of hypoglycemic episodes
for example). Therefore, insulin detemir can be considered
as a valuable new option for basal therapy in patients with
type 1 or type 2 diabetes.
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